Transcriptional regulation and induction of apoptosis: Implications for the use of monomeric p53 variants in gene therapy

Gene Therapy

Volumn 5, Issue 12, 1998, Pages 1631-1641

  Merkle, C ^a   Fritsche, M ^a   Mundt, M ^a   Jahne R ^a   Groner, B ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

Author keywords

Carboxy terminal deletions; Induction of apoptosis; Oligomerisation; p53; Transactivation

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN P53; SOMATOMEDIN C RECEPTOR; TETRACYCLINE;

APOPTOSIS; ARTICLE; CANCER; CARBOXY TERMINAL SEQUENCE; CELL CYCLE; CONTROLLED STUDY; DELETION MUTANT; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION; TRANSCRIPTION REGULATION;

EID: 0032433898     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300773     Document Type: Article

References (13)

1. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-318.
2. Graeber TG et al. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol Cell Biol 1994; 14: 6264-6277.
3. Lane DP. Cancer. p53, guardian of the genome. Nature 1992; 358: 15-16.
4. Wang P et al. p53 domains: structure, oligomerization, and transformation. Mol Cell Biol 1994; 14: 5182-5191.
5. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 1993; 7: 2556-2564.
6. Bargonetti J et al. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev 1993; 7: 2565-2574.
7. Kern SE et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 1991; 252: 1708-1711.
8. Funk WD et al. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol Cell Biol 1992; 12: 2866-2871.
9. El-Deiry WS et al. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45-49.
10. El-Deiry WS et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
11. Harper JW et al. The p21 Cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases. Cell 1993; 75: 805-816.
12. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 1572-1583.
13. Zauberman A et al. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995; 23: 2584-2592.